GlassScriptPhysician profile
Franklin L Chen
NPI 1992979736
$306,840.28
in general payments reported to CMS, 2019-2025
38 companies · $48K in 2025
The $48K reported for 2025 was more than what 93% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $25K · 2021: $30K · 2022: $39K · 2023: $27K · 2024: $54K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Food and Beverage: $5,266 · Travel and Lodging: $4,998 · Consulting Fee: $2,100 · Education: $17.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,253.00 |
| Food and Beverage | $5,265.85 |
| Travel and Lodging | $4,997.80 |
| Consulting Fee | $2,100.00 |
| Education | $17.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $70,786.95 | 2019-2025 | Venclexta |
| Janssen Biotech, INC. | $52,313.28 | 2019-2025 | Carvykti, Rybrevant, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $49,494.43 | 2019-2022 | |
| Genzyme Corporation | $47,851.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $45,078.64 | 2021-2025 | Ojjaara, Blenrep |
| Amgen INC. | $30,648.27 | 2019-2024 | Blincyto |
| Janssen Scientific Affairs, LLC | $2,165.59 | 2020-2025 | Tecvayli, Talvey, Darzalex |
| Celgene Corporation | $1,832.77 | 2021-2023 | Pomalyst |
| Genentech USA, INC. | $1,713.88 | 2020-2025 | Venclexta |
| Seagen INC. | $1,375.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $950.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $555.93 | 2020-2024 | Calquence, Tagrisso |
| Pfizer INC. | $343.47 | 2024-2025 | |
| Sobi, INC | $253.95 | 2024-2025 | |
| Adc Therapeutics America, INC. | $246.27 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $177.45 | 2021 | |
| Incyte Corporation | $163.25 | 2024-2025 | Jakafi, Niktimvo |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2024 | Iclusig |
| Gilead Sciences, INC. | $119.75 | 2021 | |
| Karyopharm Therapeutics INC. | $109.65 | 2022 | |
| Beone Medicines USA, INC. | $97.21 | 2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $57.65 | 2024-2025 | Clonoseq |
| Legend Biotech USA INC. | $51.78 | 2025 | Carvykti |
| Sanofi-Aventis U.S. LLC | $48.77 | 2024 | |
| Kite Pharma, INC. | $46.88 | 2023-2025 | Yescarta |
| Cycle Pharmaceuticals INC | $45.60 | 2025 | Phyrago |
| Astellas Pharma US INC | $42.43 | 2025 | Xospata |
| Novartis Pharmaceuticals Corporation | $38.15 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $25.83 | 2025 | Lynozyfic |
| Tempus Ai, INC | $24.74 | 2025 | Xt Cdx |
| Syndax Pharmaceuticals, INC. | $20.80 | 2025 | |
| Stemline Therapeutics INC. | $19.92 | 2025 | Orserdu |
| Merck Sharp & Dohme LLC | $15.11 | 2025 | Prevymis |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franklin Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.